Nick James

Professor of Prostate and Bladder Cancer Research. Interests: from novel diagnostics to care of advanced disease and novel trial design

[Belgian Red Devils @BelRedDevils]

Overturn this. 🧏‍♂️ #USABEL

[Nick James @Prof_Nick_James]

I never viewed it as in any way clinically relevant. It’s just a way of counting relapses consistently for trials. Threshold for imaging should be driven by the imaging you have available. Plus the relevant pathology etc.

[Alison Tree 💙 @alison_tree]

Great article below 👇 - it’s time to rethink biochemical relapse thresholds. Many oncologists are no longer waiting for nadir+2 to image, so I support the need for a new framework for practice.

[Syed A Hussain @ProfSyedHussain]

Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery | Cancer research | The Guardian. Great to see our RADio trial highlighted by guardian. Study investigated addition of Durvalumab to concurrent chemo RT. @prof_nick_james https://t.co/ogy0kkFWqT

[Nick James @Prof_Nick_James]

Would be interesting to do this piece of research. However, as per my previous comments, PROTEUS has compared 2 non standard approaches with no SOC control so hard to make sense of it.

[James Janopaul-Naylor @jjnaylor02]

Do we need MMAI on prostate biopsies from PROTEUS to inform choice for periop ADT?

[Nick James @Prof_Nick_James]

We have a number of professors of statistics on the author list and the paper has passed through peer statistical review at a high impact journal. I cannot comment on the specifics of the stats comments in this post but am confident in my co-authors’ knowledge in this area.

[Clive Peedell @cpeedell]

My brain doesn’t do stats. What do STAMPEDE team think of this critique, @Prof_Nick_James ?

[Nick James @Prof_Nick_James]

Great to meet you all!

[Dr. Muhammad Nawaz Khan Niazi @drnawazniazi1]

Delighted to have an Inspiring and insightful discussion with @Prof_Nick_James @ProfSyedHussain @saadnasir01 at the ASCO2026.

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

New data in @Annals_Oncology: A target trial emulation of >229K obese, nondiabetic adults shows GLP-1RA use is associated with a 41% reduction in obesity-associated cancers compared to lifestyle modifications alone (HR 0.59). - Congratulations to Aparna Kamat, Arthur Hsu, @pedroramirezMD & entire @MethodistHosp team

https://t.co/QcxF7hDneX
@SGO_org

[Nick James @Prof_Nick_James]

Delighted that our STAMPEDE paper on abiraterone therapy selection with MMAI in high risk M0 HSPC now out. https://t.co/5TF3nHt0DZ

[Rob Calvert @RobCalvert18]

80% disease free survival at 1 year in bladder preserving Rx for MIBC using durvalumab and chemoradiotherapy. A significant step up from historical controls @Prof_Nick_James

[Nick James @Prof_Nick_James]

Exactly, only around half, yet still looks v similar to other groups’ TMT data. A subgroup had biopsy only and still did fine. We presented this at ESMO a while ago (but not published sorry)

[Cedric Peters @CedricPetersRT]

@Prof_Nick_James I cite your data often! But in this trial 56% received a complete resection so hard to argue against it.

[Bradley Stish @DrStish]

@CedricPetersRT @Prof_Nick_James The data showing ⬇️outcomes when complete TURBT not done is almost certainly a surrogate marker of more advanced disease, which not surprisingly does worse. Appreciate @Prof_Nick_James sharing their experience. An extra procedure + creation of more hypoxia does seem low value.

[David Cameron @David_Cameron]

Today’s decision from the Health Secretary on prostate cancer screening is a missed opportunity - too timid, too slow, and lacking the bold ambition that we so desperately wanted to see.

As I set out last week, I fundamentally disagree with the National Screening Committee’s advice on a future screening programme for prostate cancer, which is far too narrow. I strongly believe that if we are really to get on top of prostate cancer - the most common cancer in British men - then a proper, targeted screening programme for all those at higher risk is needed… and needed now.

I welcome expanded provision of focal therapy, which I benefited from last year with my own cancer; this must be an urgent priority to make available across the NHS. And the recognition that more work is needed to screen at risk groups, such as black men, is important.

But this was an opportunity for bold, decisive, life-saving action - action that would help save the heartache of too many families losing a loved-one to this disease. That, sadly, has been missed. We will continue the campaign to urge the Government to go further, faster and put in place a progressive policy that includes a proper screening programme for the most at-risk men.

[Nick James @Prof_Nick_James]

Agree but would go even further and roll out to all men over 45

[David Cameron @David_Cameron]

Today’s decision from the Health Secretary on prostate cancer screening is a missed opportunity - too timid, too slow, and lacking the bold ambition that we so desperately wanted to see.

As I set out last week, I fundamentally disagree with the National Screening Committee’s advice on a future screening programme for prostate cancer, which is far too narrow. I strongly believe that if we are really to get on top of prostate cancer - the most common cancer in British men - then a proper, targeted screening programme for all those at higher risk is needed… and needed now.

I welcome expanded provision of focal therapy, which I benefited from last year with my own cancer; this must be an urgent priority to make available across the NHS. And the recognition that more work is needed to screen at risk groups, such as black men, is important.

But this was an opportunity for bold, decisive, life-saving action - action that would help save the heartache of too many families losing a loved-one to this disease. That, sadly, has been missed. We will continue the campaign to urge the Government to go further, faster and put in place a progressive policy that includes a proper screening programme for the most at-risk men.

[Nick James @Prof_Nick_James]

Nice piece of coverage for our RADIO data presented at #asco26 https://t.co/OK6VMt4Mvj

[Nick James @Prof_Nick_James]

Not sure how failure to make things worse is a good outcome for an expensive treatment!

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨Day FOUR #ASCO26
Post by @OncoAlert Faculty @DrChoueiri 🇺🇸

POTOMAC
5-year OS update presented by Dr Maria De Santis: Durvalumab + BCG (I+M) continues to show no detriment to OS vs BCG alone in BCG-naive high-risk NMIBC (5-yr OS 87.6% vs 86.3%), with no major impact on quality of life

@DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @tompowles1 🇬🇧 @brian_rini 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @Erman_Akkus 🇹🇷 @yekeduz_emre 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

[Nick James @Prof_Nick_James]

Spot on

[Rishi Sunak @RishiSunak]

There’s no getting away from the fact that this is a missed opportunity for men’s health.

The chance to stop more fathers, brothers and sons dying before their time has not been seized.

I will continue to campaign with @PCR_News for a targeted screening programme for prostate cancer because the evidence shows that will save lives.

[Rishi Sunak @RishiSunak]

There’s no getting away from the fact that this is a missed opportunity for men’s health.

The chance to stop more fathers, brothers and sons dying before their time has not been seized.

I will continue to campaign with @PCR_News for a targeted screening programme for prostate cancer because the evidence shows that will save lives.

[Nick James @Prof_Nick_James]

Maybe cite our data - we have the largest series! https://t.co/XgrsCOrOUI. It��s a made up
criterion to help get urologists to buy into referral by making them do extra stuff. No proven benefit and possible harm eg perforation.

[Cedric Peters @CedricPetersRT]

@Prof_Nick_James In clinical practice I still see a lot of push back if you downplay the role of TURB as part of treatment. Some clinicians view it as an integral part of bladder sparing. No (maximal) TURB, no chemorads.

[Nick James @Prof_Nick_James]

@Soum_Roy_RadOnc Yes. No proven benefit to dose escalation- effectively done by the sensitiser

[Nick James @Prof_Nick_James]

In fact never done this. Has not been a criteria for any of our chemoRT studies, nor is it done much out of trials. Pts will have had a diagnostic TUR only

[Cedric Peters @CedricPetersRT]

@Prof_Nick_James Do you still do a maximal TURB before chemoRT?